Clinical Trial Update: Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts [Phase 1]

View source ↗

Summary

Phase 1 safety study update of sublingual immunotherapy tablets containing house dust mite allergen extracts; the trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• House Dust Mite Allergy

Drugs mentioned

• House dust mite allergen extract sublingual immunotherapy tablet (house dust mite allergen extract sublingual immunotherapy tablet)

Snippet

Sponsor: Stallergenes Greer | Conditions: Asthma, House Dust Mite Allergy | Phase 1 | Status: COMPLETED